0001193125-20-289027.txt : 20201230 0001193125-20-289027.hdr.sgml : 20201230 20201109155651 ACCESSION NUMBER: 0001193125-20-289027 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20201109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROTEOSTASIS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001445283 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 80 GUEST STREET STREET 2: 5TH FLOOR CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: 617-225-0096 MAIL ADDRESS: STREET 1: 80 GUEST STREET STREET 2: 5TH FLOOR CITY: BOSTON STATE: MA ZIP: 02135 FORMER COMPANY: FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS, INC. DATE OF NAME CHANGE: 20140813 FORMER COMPANY: FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS INC DATE OF NAME CHANGE: 20080916 CORRESP 1 filename1.htm CORRESP

PROTEOSTASIS THERAPEUTICS, INC.

November 9, 2020

VIA EDGAR

Division of Corporation Finance

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Re: Acceleration Request of Proteostasis Therapeutics, Inc.

Registration Statement on Form S-4, as amended

Originally filed on September 23, 2020 (File No. 333-248993)

Ladies and Gentlemen:

In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Proteostasis Therapeutics, Inc. (the “Company”) hereby requests acceleration of the effective date of the Registration Statement on Form S-4 (File No. 333-248993), as amended (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern Time on November 10, 2020, or as soon as possible thereafter.

The Company hereby authorizes Marianne Sarrazin or Courtney Thorne of Cooley LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.

The Company respectfully requests that it be notified of such effectiveness by a telephone call to Attorney Sarrazin or Attorney Thorne at (415) 693-2157 or (617) 937-2318, respectively, and that such effectiveness also be confirmed in writing. Any questions regarding this request may be addressed to Attorney Sarrazin or Attorney Thorne.

 

Very truly yours,

 

PROTEOSTASIS THERAPEUTICS, INC.

/s/ Meenu Chhabra

Meenu Chhabra

Chief Executive Officer

 

cc:

Miguel J. Vega, Esq.

Marc A. Recht, Esq.

Marianne C. Sarrazin, Esq.

Courtney T. Thorne, Esq.

Cooley LLP

Richard Peters, M.D., Ph.D.

Yumanity Therapeutics, Inc.

John T. Haggerty, Esq.

Jesse Nevarez, Esq.

Goodwin Procter LLP